News

Palmar-plantar psoriasis? Anti-TNF therapy may be culprit

Publish date: October 4, 2013

 

EXPERT ANALYSIS FROM PERSPECTIVES IN RHEUMATIC DISEASES 2013

The meeting was held by Global Academy for Medical Education. GAME and this news organization are owned by Frontline Medical Communications.

Dr. Gordon reported receiving research support and/or honoraria from AbbVie, Amgen, and other companies. Dr. McInnes reported serving as a speaker, adviser, and/or researcher for Janssen, Roche, and other companies.

Pages

Recommended Reading

Most American RA patients quit biologics after 2 years
MDedge Rheumatology
Infliximab, IV steroid combos with methotrexate appear comparable in early RA
MDedge Rheumatology
Combo of smoking while overweight boosts RA incidence
MDedge Rheumatology
Tofacitinib rapidly improves RA signs and symptoms
MDedge Rheumatology
Omega-3 fatty acid found in fish may reduce RA risk
MDedge Rheumatology
Biosimilar matches up well against infliximab in RA trial
MDedge Rheumatology
Patient global score predicts postbiological quality of life gain in RA
MDedge Rheumatology
NSAIDs, methotrexate used most for rheumatoid arthritis
MDedge Rheumatology
Study sheds light on exacerbation risks with RA lung disease
MDedge Rheumatology
RA disease activity assessed differently by patients, physicians, and ultrasound
MDedge Rheumatology